Qiagen击败了2025年Q4的预期收入,提高了2026年的指导意见,并看到分析家反应喜忧参半。 Qiagen beat earnings expectations in Q4 2025, raised 2026 guidance, and saw mixed analyst reactions.

Qiagen报告说,2026年2月4日的Q4收入比预期的要高,其中62美元为EPS,5.4042亿美元为收入,同比增长3.6%。 Qiagen reported stronger-than-expected Q4 earnings on February 4, 2026, with $0.62 EPS and $540.42 million in revenue, up 3.6% year-over-year. 该公司将其2026年全年收入指导提高到每股2.50美元,其第一季度展望提高到0.54美元。 The company raised its full-year 2026 earnings guidance to $2.50 per share and its first-quarter outlook to $0.54. JPorgan将其价格目标提高到60美元,并引述了潜在的倒值,而花旗集团则将其目标降低到55.00美元。 JPMorgan raised its price target to $60, citing potential upside, while Citigroup lowered its target to $55.00. 股票交易额约51.19美元,市场上限为108亿美元,并获得一致的“控股”评级。 The stock, trading around $51.19, has a market cap of $10.8 billion and a consensus "hold" rating.